The HRT controversy: observational studies and RCTs fall in line

The Lancet

Volumn 373, Issue 9671, 2009, Pages 1233-1235

  Vandenbroucke, Jan P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL RESEARCH; MENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

EID: 64049113146     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60708-X     Document Type: Note

References (14)

1. Hernán M.A., Alonso A., Logan R., et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 19 (2008) 766-779
2. Prentice R.L., Chlebowski R.T., Stefanick M.L., et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 167 (2008) 1207-1216
3. Reeves G.K., Beral V., Green J., Gathani T., Bull D., and for the Million Women Study Collaborators. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7 (2006) 910-918
4. Prentice R.L., Chlebowski R.T., Stefanick M.L., et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 167 (2008) 1407-1415
5. Prentice R.L., Langer R., Stefanick M.L., et al., for the Women's Health Initiative Investigators. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 162 (2005) 404-414
6. Prentice R.L., Langer R.D., Stefanick M.L., et al., for the Women's Health Initiative Investigators. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 163 (2006) 589-599
7. Hoover R.N. The sound and the fury: was it all worth it?. Epidemiology 19 (2008) 780-782
8. Stampfer M.J. ITT for observational data: worst of both worlds?. Epidemiology 19 (2008) 783-784
9. Prentice R.L. Data analysis methods and the reliability of analytic epidemiologic research. Epidemiology 19 (2008) 785-788
10. Hernán M.A., and Robins J.M. Authors' response: part I. Observational studies analyzed like randomized experiments: best of both worlds. Epidemiology 19 (2008) 789-792
11. Willett W.C., Manson J.E., and Grodstein F. Author's response: part II. Epidemiology 19 (2008) 793
12. Wilcox A., and Wacholder S. Observational data and clinical trials: narrowing the gap?. Epidemiology 19 (2008) 765
13. Vandenbroucke J.P. When are observational studies as credible as randomised trials?. Lancet 363 (2004) 1728-1731
14. Vandenbroucke J.P., and Psaty B.M. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA 300 (2008) 2417-2419